These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 34645283)

  • 21. Retrospective review of Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrate for reversal of DOAC-Associated Intracranial Hemorrhage.
    Troyer C; Nguyen W; Xie A; Wimer D
    J Thromb Thrombolysis; 2023 Jan; 55(1):149-155. PubMed ID: 36355324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Andexanet Alfa (Andexxa) Formulary Review.
    Beik N; Reddy P; Sylvester KW; Connell NT; Giugliano RP; Piazza G; Connors JM
    Crit Pathw Cardiol; 2019 Jun; 18(2):66-71. PubMed ID: 31094731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world clinical outcomes among US Veterans with oral factor xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate.
    Sutton SS; Magagnoli J; Cummings TH; Dettling T; Lovelace B; Christoph MJ; Hardin JW
    J Thromb Thrombolysis; 2023 Jul; 56(1):137-146. PubMed ID: 37219827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of andexanet alfa versus four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-related intracranial hemorrhage in the US.
    Fanikos J; Goldstein JN; Lovelace B; Beaubrun AC; Blissett RS; Aragão F
    J Med Econ; 2022; 25(1):309-320. PubMed ID: 35168455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Administration of andexanet alfa for traumatic intracranial hemorrhage in the setting of massive apixaban overdose: A case report.
    Jenniches D; Kerns AF; DelBianco J; Stripp MP; Philp AS
    Am J Health Syst Pharm; 2023 Nov; 80(23):1722-1728. PubMed ID: 37688311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage.
    Lipski M; Pasciolla S; Wojcik K; Jankowitz B; Igneri LA
    J Thromb Thrombolysis; 2023 Apr; 55(3):519-526. PubMed ID: 36566473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reversal of oral anticoagulation in patients with acute intracerebral hemorrhage.
    Kuramatsu JB; Sembill JA; Huttner HB
    Crit Care; 2019 Jun; 23(1):206. PubMed ID: 31171018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study.
    Dobesh PP; Fermann GJ; Christoph MJ; Koch B; Lesén E; Chen H; Lovelace B; Dettling T; Danese M; Ulloa J; Danese S; Coleman CI
    Res Pract Thromb Haemost; 2023 Aug; 7(6):102192. PubMed ID: 37753225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates.
    Panos NG; Cook AM; John S; Jones GM;
    Circulation; 2020 May; 141(21):1681-1689. PubMed ID: 32264698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Andexanet Alfa or Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal in Acute Major Bleeding: A Systematic Review and Meta-Analysis.
    Nederpelt CJ; Naar L; Krijnen P; le Cessie S; Kaafarani HMA; Huisman MV; Velmahos GC; Schipper IB
    Crit Care Med; 2021 Oct; 49(10):e1025-e1036. PubMed ID: 33967205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes Associated With 4-Factor Prothrombin Complex Concentrate Administration to Reverse Oral Factor Xa Inhibitors in Bleeding Patients.
    Highsmith EA; Morton C; Varnado S; Donahue KR; Sulhan S; Lista A
    J Clin Pharmacol; 2021 May; 61(5):598-605. PubMed ID: 33094836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Andexanet alfa: the best antidote for factor Xa inhibitors?].
    Klok FA; Huisman MV
    Ned Tijdschr Geneeskd; 2019 Jun; 163():. PubMed ID: 31283119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thirty-day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life-threatening direct oral anticoagulant-related bleeding.
    Cohen AT; Lewis M; Connor A; Connolly SJ; Yue P; Curnutte J; Alikhan R; MacCallum P; Tan J; Green L
    J Am Coll Emerg Physicians Open; 2022 Apr; 3(2):e12655. PubMed ID: 35280921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emergent reversal of oral factor Xa inhibitors with four-factor prothrombin complex concentrate.
    Lipari L; Yang S; Milligan B; Blunck J
    Am J Emerg Med; 2020 Dec; 38(12):2641-2645. PubMed ID: 33041150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of andexanet alpha in the Polish setting: An interdisciplinary protocol. Expert consensus statement of the Polish Cardiac Society.
    Kazimierczyk E; Dąbrowska M; Gierlotka M; Kapica-Topczewska K; Karaszewski B; Kobayashi A; Krasiński Z; Kubica J; Kułakowska A; Kurek K; Ładny R; Pleban E; Rejdak K; Rydzewska G; Słowik A; Szopiński P; Woźniak A; Tycińska A
    Kardiol Pol; 2024; 82(1):123-139. PubMed ID: 38230495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage.
    Ammar AA; Ammar MA; Owusu KA; Brown SC; Kaddouh F; Elsamadicy AA; Acosta JN; Falcone GJ
    Neurocrit Care; 2021 Aug; 35(1):255-261. PubMed ID: 33403588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of andexanet alfa and 4-factor prothrombin complex concentrate in intracranial hemorrhage.
    Oh ES; Schulze P; Diaz F; Shah K; Rios J; Silverman ME
    Am J Emerg Med; 2023 Feb; 64():74-77. PubMed ID: 36463661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage.
    Gerner ST; Kuramatsu JB; Sembill JA; Sprügel MI; Endres M; Haeusler KG; Vajkoczy P; Ringleb PA; Purrucker J; Rizos T; Erbguth F; Schellinger PD; Fink GR; Stetefeld H; Schneider H; Neugebauer H; Röther J; Claßen J; Michalski D; Dörfler A; Schwab S; Huttner HB;
    Ann Neurol; 2018 Jan; 83(1):186-196. PubMed ID: 29314216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors.
    Nafee T; Aslam A; Chi G; Pahlavani S; Nimri D; Kuchkuntla AR; Talib U; Michalak N; Daaboul Y; Korjian S; Gallo A; Gibson CM
    Expert Rev Cardiovasc Ther; 2017 Apr; 15(4):237-245. PubMed ID: 28282497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In factor Xa inhibitor-related acute ICH, andexanet vs. usual care improved hemostatic efficacy but increased thrombotic events.
    Hunter BR; Kirschner JM
    Ann Intern Med; 2024 Sep; 177(9):JC101. PubMed ID: 39222512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.